Last updated: 8 January 2024 at 4:40pm EST

Joshua Hexter Net Worth



Joshua Hexter biography

Joshua Hexter serves as Chief Operating and Business Officer of the Company. Prior to his appointment, Mr. Hexter served as Chief Business Officer at BrainsWay Ltd. (Nasdaq/TASE: BWAY) from 2018 to 2019, a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation products. From 2013 to 2018, Mr. Hexter served as Chief Operating Officer and VP Business Development of the Company and from 2007 to 2013, Mr. Hexter was a Director or Executive Director of BioLineRx Ltd. (Nasdaq/TASE: BLRX), a biopharmaceutical development company dedicated to identifying, in-licensing and developing innovative therapeutic candidates. Prior to his employment with BioLineRx, Mr. Hexter was a member of the board of directors and Chief Executive Officer of Biosensor Systems Design, Inc., a company developing market-driven biosensors. Mr. Hexter holds a bachelor’s degree from the University of Wisconsin and a master’s degree in management from Boston University.

What is the salary of Joshua Hexter?

As the Chief Operating and Business Officer of Oramed Pharmaceuticals, Inc, the total compensation of Joshua Hexter at Oramed Pharmaceuticals, Inc is $507,598. There are 3 executives at Oramed Pharmaceuticals, Inc getting paid more, with Nadav Kidron having the highest compensation of $1,551,100.



How old is Joshua Hexter?

Joshua Hexter is 49, he's been the Chief Operating and Business Officer of Oramed Pharmaceuticals, Inc since 2019. There are 9 older and 5 younger executives at Oramed Pharmaceuticals, Inc. The oldest executive at Oramed Pharmaceuticals, Inc is Dr. Miriam Kidron Ph.D., 81, who is the Chief Scientific Officer & Director.

What's Joshua Hexter's mailing address?

Joshua's mailing address filed with the SEC is 20 MAMILLA AVENUE, , JERUSALEM, L3, 9414904.

Insiders trading at Oramed Pharmaceuticals, Inc

Over the last 17 years, insiders at Oramed Pharmaceuticals, Inc have traded over $7,377,390 worth of Oramed Pharmaceuticals, Inc stock and bought 881,642 units worth $3,583,418 . The most active insiders traders include Miriam Kidron, Leonard Sank e Nadav Kidron. On average, Oramed Pharmaceuticals, Inc executives and independent directors trade stock every 111 days with the average trade being worth of $97,149. The most recent stock trade was executed by Arie Mayer on 3 April 2023, trading 8,809 units of ORMP stock currently worth $19,556.



What does Oramed Pharmaceuticals, Inc do?

oramed pharmaceuticals (nasdaqcm:ormp) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection. through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 trials under the usfda, the company is seeking to revolutionize the treatment of diabetes. read more: http://www.oramed.com/investors/corporate-presentation watch: https://www.youtube.com/watch?v=5qchxtdv9eg



What does Oramed Pharmaceuticals, Inc's logo look like?

Oramed Pharmaceuticals, Inc logo

Oramed Pharmaceuticals, Inc executives and stock owners

Oramed Pharmaceuticals, Inc executives and other stock owners filed with the SEC include: